Press Releases

22-11-2023

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)

MORE >

21-11-2023

Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.

MORE >

14-11-2023, 12:04 CET (Ad hoc press release)

Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

MORE >

14-11-2023

Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023

MORE >

23-10-2023

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

MORE >

20-10-2023

Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG

MORE >

20-10-2023, 15:18 CEST (Ad hoc press release)

Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets

MORE >

17-10-2023, 16:57 CEST (Ad hoc press release)

Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.

MORE >

10-10-2023

Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225

MORE >

28-09-2023

Eckert & Ziegler Receives Award for Professional Training

MORE >

25-09-2023, 23:17 CEST (Ad hoc press release)

Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma

MORE >

13-09-2023

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

MORE >

10-08-2023

Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

MORE >

21-07-2023, 15:21 CEST (Ad hoc press release)

Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.

MORE >

08-06-2023

Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma

MORE >

07-06-2023

ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.

MORE >

30-05-2023

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

MORE >

15-05-2023

Reorganization in the Executive Board of Eckert & Ziegler

MORE >

11-05-2023

Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

MORE >

08-05-2023

Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

MORE >

25-04-2023, 17:59 CEST (Ad hoc press release)

Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance

MORE >

20-04-2023

Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

MORE >

12-04-2023

Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site

MORE >

04-04-2023

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

MORE >

30-03-2023

Eckert & Ziegler: Successful fiscal year 2022